期刊文献+

Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer:Quo vadis? 被引量:4

Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer:Quo vadis?
在线阅读 下载PDF
导出
摘要 Breast cancer(BC) is the most frequent type of non skin cancer among women and a major leading cause of cancer-related deaths in Western countries. It is substantial to discover novel biomarkers with diagnostic, prognostic or predictive usefulness as well as therapeutic value for BC. Micro-RNAs(miR NAs) belong to a novel class of endogenous interfering RNAs that play a crucial role in post transcriptional gene silencing through m RNA targeting and, thus, are involved in many biological processes encompassing apoptosis,cell-cycle control, cell proliferation, DNA repair, immunity, metabolism, stress, aging, etc. Mi RNAs exert their action mainly in a tumor suppressive or oncogenic manner. The specific aberrant expression patterns of miR NAs in BC that are detected with the use of highthroughput technologies reflect their key role in cancer initiation, progression, migration, invasion and metastasis. The detection of circulating extracellular miR NAs in plasma of BC patients may provide novel, non-invasive biomarkers in favor of BC diagnosis and prognosis and,at the same time, accumulating evidence has underscored the possible contribution of miR NAs as valuable biomarkers to predict response to chemotherapy or radiotherapy. Data from in vitro and in vivo studies on BC have revealed promising therapeutic approaches via mi RNA delivery and mi RNA inhibition. The purpose of this review is to explore the ontological role of miR NAs in BC etiopathogenesis as well as to highlight their potential, not only as non-invasive circulating biomarkers with diagnostic and prognostic significance, but also as treatment response predictors and therapeutic targets aiding BC management. Breast cancer(BC) is the most frequent type of non skin cancer among women and a major leading cause of cancer-related deaths in Western countries. It is substantial to discover novel biomarkers with diagnostic, prognostic or predictive usefulness as well as therapeutic value for BC. Micro-RNAs(miR NAs) belong to a novel class of endogenous interfering RNAs that play a crucial role in post transcriptional gene silencing through m RNA targeting and, thus, are involved in many biological processes encompassing apoptosis,cell-cycle control, cell proliferation, DNA repair, immunity, metabolism, stress, aging, etc. Mi RNAs exert their action mainly in a tumor suppressive or oncogenic manner. The specific aberrant expression patterns of miR NAs in BC that are detected with the use of highthroughput technologies reflect their key role in cancer initiation, progression, migration, invasion and metastasis. The detection of circulating extracellular miR NAs in plasma of BC patients may provide novel, non-invasive biomarkers in favor of BC diagnosis and prognosis and,at the same time, accumulating evidence has underscored the possible contribution of miR NAs as valuable biomarkers to predict response to chemotherapy or radiotherapy. Data from in vitro and in vivo studies on BC have revealed promising therapeutic approaches via mi RNA delivery and mi RNA inhibition. The purpose of this review is to explore the ontological role of miR NAs in BC etiopathogenesis as well as to highlight their potential, not only as non-invasive circulating biomarkers with diagnostic and prognostic significance, but also as treatment response predictors and therapeutic targets aiding BC management.
出处 《World Journal of Clinical Oncology》 CAS 2014年第2期71-81,共11页 世界临床肿瘤学杂志(英文版)
关键词 BIOMARKER Breast CANCER CANCER diagnosis MICRO-RNA ONCOGENE Therapy Tumor SUPPRESSOR Biomarker Breast cancer Cancer diagnosis Micro-RNA Oncogene Therapy Tumor suppressor
  • 相关文献

参考文献1

二级参考文献51

  • 1Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005; 11:1753-1761.
  • 2Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005; 309:1519-1524.
  • 3Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
  • 4Fitzgerald K. RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes. Curr Opin Drug Discov Dev 2005, 8:557-566.
  • 5Brennecke J, Stark A, Russell R.B, Cohen SM. Principles of microRNA-target recognition. PLoS Biol.2005; 3:e85.
  • 6Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122:6-7.
  • 7Chen CZ, Li L, Lodish HF, Bartel DE MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303:83- 86.
  • 8Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94:776-780.
  • 9Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006; 16:4-9.
  • 10Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-269.

共引文献210

同被引文献21

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部